EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
Journal article published in 2019 by
Anna Dorothea Wagner 
,
Heike I. Grabsch,
Murielle Mauer,
Sandrine Marreaud,
Carmela Caballero,
Peter Thuss-Patience,
Lothar Mueller,
Annelie Elme,
Markus Hermann Moehler,
Uwe Martens,
Yoon-Koo Kang,
Sun Young Rha ,
Annemieke Cats,
Masanori Tokunaga,
Florian Lordick
,
Heike I. Grabsch,
Murielle Mauer,
Sandrine Marreaud,
Carmela Caballero,
Peter Thuss-Patience,
Lothar Mueller,
Annelie Elme,
Markus Hermann Moehler,
Uwe Martens,
Yoon-Koo Kang,
Sun Young Rha ,
Annemieke Cats,
Masanori Tokunaga,
Florian Lordick
This paper is made freely available by the publisher.
Full text: Download
Data provided by 